Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11443734 | 0.84 | ESR1 (0.43) | ESR1ESR2BRD4HSP90AA1 | |
| SCHEMBL5514165 | 0.79 | ESR1 (0.40) | ESR1ESR2BRD4HSP90AA1 | |
| SCHEMBL5506253 | 0.78 | ESR1 (0.39) | ESR1ESR2BRD4HSP90AA1 | |
| SCHEMBL1759343 | 0.69 | MAPT (0.54) | ESR1ESR2 | |
| SCHEMBL1101176 | 0.69 | ESR1 (0.45) | ESR1ESR2HSP90AA1 | |
| SCHEMBL5511923 | 0.69 | ESR1 (0.42) | ESR1ESR2HSP90AA1 | |
| SCHEMBL5511697 | 0.68 | ESR1 (0.41) | ESR1ESR2HSP90AA1 | |
| SCHEMBL5509963 | 0.68 | AHR (0.44) | ESR1ESR2HSP90AA1 | |
| SCHEMBL5508112 | 0.64 | ESR1 (0.63) | ESR1ESR2HSP90AA1 | |
| SCHEMBL2137945 | 0.64 | ESR1 (0.61) | ESR1ESR2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166725-B2 | Benzo[d]isoxazol-3-ol DAAO inhibitors | SEPRACOR INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166725-B2 | Benzo[d]isoxazol-3-ol DAAO inhibitors | SEPRACOR INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166725-B2 | Benzo[d]isoxazol-3-ol DAAO inhibitors | SEPRACOR INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1711478-A2 | BENZO [D]ISOXAZOL-3-OL DAAO INHIBITORS | Sepracor Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005066143-A2 | BENZO[D]ISOXAZOL-3-OL DAAO INHIBITORS | SEPRACOR INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005066143-A2 | BENZO[D]ISOXAZOL-3-OL DAAO INHIBITORS | SEPRACOR INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050143434-A1 | Benzo[d]isoxazol-3-ol DAAO inhibitors | SEPRACOR INC. (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143434-A1 | Benzo[d]isoxazol-3-ol DAAO inhibitors | DDO, DAO, CACNA1S | ESR1 2250/4885ESR2 3052/4885BRD4 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.